FDA Lifts Clinical Hold On BioCryst's BCX9930 Program For Rare Blood Disorder


27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


  • The FDA lifted a partial clinical hold on BioCryst Pharmaceuticals Inc's (NASDAQ:BCRX) BCX9930 program. The company will resume enrollment under revised protocols at a reduced dose of 400 mg twice daily of BCX9930. 
  • This includes the REDEEM-1 & REDEEM-2 trials in paroxysmal nocturnal hemoglobinuria and the RENEW trial in C3 glomerulopathy, immunoglobulin A nephropathy, and primary membranous nephropathy.
  • Clinical evidence and recent laboratory studies have informed the company's hypothesis that crystals form in the kidneys of some patients. 
  • The company believes that lowering the dose to 400 mg and ensuring adequate hydration dilutes the drug concentration in the urine below the threshold where crystals can form.
  • In April, BioCryst voluntarily paused enrollment in BCX9930 trials while investigating elevated serum creatinine (SCr) in some patients at the 500 mg twice daily dose. 
  • The FDA subsequently placed the program on partial clinical hold. 
  • PNH patients naive to C5 inhibitor therapy who received 400 mg twice daily in the Phase 1 program (n=7) experienced a mean change from baseline increase in hemoglobin of 4.3 g/dL and required no transfusions.
  • No patients experienced an elevation in their SCr during dose-ranging at the 400 mg twice daily dose. All observed cases of SCr elevations occurred at 500 mg twice daily.
  • Q2 Orladeyo revenue reached $65.2 million, with total sales of $65.5 million, +31.2% Y/Y, beating the consensus of $64.31 million.
  • EPS loss came in at $(0.32) up from $(0.24) a year ago, beating the consensus of $(0.34).
  • Guidance: BioCryst expects FY22 Orladeyo sales of $255 million - $265 million. 
  • Price Action: BCRX shares are up 20.6% at $13.45 during the market session on the last check Thursday.

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechEarningsNewsGuidanceHealth CareFDAMoversTrading IdeasGeneralBriefswhy it's moving